Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.

Leukemia - 1 Apr 2015

Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang Y L

Abstract excerpt

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has produced remarkable clinical response in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. We previously reported the identification of BTK(C481S) mutation in a CLL patient who progressed following 21-month ibrutinib therapy. Initial characterization at structural and biochemical levels revealed that the mutation disrupts the covalent binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Pyrazoles

Share to Pyrroles

Share to Thiazoles

Source

Identifiers

PMID: 25189416
DOI: 10.1038/leu.2014.263

Genes

BTK

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.PMID 25189416Read ↗

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.Semantic proximity Read ↗

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Semantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.Semantic proximity Read ↗

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsSemantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read ↗

Targeting Bruton's Tyrosine Kinase in CLL.Semantic proximity Read ↗

New Means and Challenges in the Targeting of BTK.Semantic proximity Read ↗

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.